Will FDA Panel Shake-Up Restore Access to Compounded Peptides?
For years, the FDA’s approach to compounded peptides has looked less like careful regulation and more like a campaign to eliminate patient access to products that compete with Big Pharma. There may at last be reason for cautious optimism. Action Alert! Listen to the audio version of this story: THE TOPLINE For too long, patients […]










